Contra-indicated in patients with known or suspected gastrointestinal obstruction.
Opioid withdrawal symptoms have occurred in patients treated with naldemedine.
- TRADE NAME: Symproic (Shionogi)
- INDICATIONS: Opioid-induced constipation in adult patients with chronic non-cancer pain
- CLASS: Opioid antagonist, Opioid receptor antagonist
- HALF-LIFE: 11 hours
- FDA APPROVAL DATE: 03/23/2017
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amiodarone, Aprepitant, Atazanavir, Captopril, Carbamazepine, Clarithromycin, Cyclosporine, Diltiazem, Erythromycin, Fluconazole, Itraconazole, Ketoconazole, Moderate or strong CYP3A inhibitors, Other opioid antagonists, P-gp inhibitors, Phenytoin, Quercetin, Quinidine, Rifampin, Ritonavir, Saquinavir, St John's Wort, Strong CYP3A inducers, Verapamil - PREGNANCY: Potential for opioid withdrawal in fetus
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 03/14/2025
